GlassScriptPhysician profile
Pauline Petrovski
NPI 1013948397
$5,240.92
in general payments reported to CMS, 2019-2025
28 companies · $1,857 in 2025
The $1,857 reported for 2025 was more than what 94% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $224 · 2020: $122 · 2021: $522 · 2022: $215 · 2023: $214 · 2024: $2,087 · 2025: $1,857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,200 · Food and Beverage: $958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,200.00 |
| Food and Beverage | $958.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $3,223.04 | 2024-2025 | |
| Abbvie INC. | $430.62 | 2019-2023 | |
| Exeltis, USA INC. | $216.30 | 2020-2024 | Slynd |
| Astellas Pharma US INC | $192.21 | 2023-2025 | Veozah |
| Sage Therapeutics, LLC | $138.33 | 2024-2025 | Zurzuvae |
| Organon LLC | $128.27 | 2021-2025 | Nexplanon |
| Pfizer INC. | $121.31 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $112.91 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $85.74 | 2021 | |
| Mayne Pharma Commercial LLC | $67.96 | 2024-2025 | |
| Hologic Sales and Service, LLC | $67.75 | 2019-2025 | Thinprep 2000 Processor, Novasure |
| Therapeuticsmd, INC. | $67.44 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $59.20 | 2019-2021 | |
| Duchesnay USA Incorporated | $46.79 | 2019-2023 | Bonjesta, Osphena |
| Meditrina | $36.15 | 2023-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $33.86 | 2021-2023 | Twirla |
| Ascend Therapeutics US, LLC | $33.11 | 2021 | |
| Conmed Corporation | $23.33 | 2025 | Airseal |
| Myovant Sciences INC. | $22.97 | 2022 | |
| Abbott Laboratories | $21.41 | 2025 | Proclaim |
| Evofem Biosciences, INC. | $21.39 | 2025 | Phexxi, Solosec, Phexx |
| Millicent US INC | $18.54 | 2025 | Femlyv |
| Amag Pharmaceuticals, INC. | $16.21 | 2019 | |
| Minerva Surgical, INC | $15.32 | 2024 | |
| Dysis Medical, INC. | $14.11 | 2021 | |
| Acessa Health INC. | $14.03 | 2021 | |
| Allergan, INC. | $12.62 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pauline Petrovski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.